Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00424788
Status:
COMPLETED
Last Update Posted:
2009-09-04
First Post:
2007-01-18
Brief Title:
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis MS
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis MS
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Natalizumab TYSABRI is a protein-based drug that is manufactured by Biogen Idec in partnership with Elan Pharmaceuticals Natalizumab is approved in the US and Europe for the treatment of Multiple Sclerosis MS The purpose of this study is to determine whether the amount of natalizumab TYSABRI that is present in your blood plasma can be reduced or eliminated by separating and removing the plasma and replacing it with other fluids a process called plasma exchange
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None